Graphical Abstract Highlights d Antimicrobial resistance is a growing threat to modern medicine d Methods to predict the effect of mutations on the actions of antibiotics are needed d The effect of mutations on the action of trimethoprim on S. aureus are studied d Free energy methods successfully classify which mutations confer resistance In Brief Fowler et al. demonstrate how alchemical free energy calculations not only can classify whether mutations in Staphylococcus aureus dihydrofolate reductase confer resistance to trimethoprim, an antibiotic, or not, but also that the method is quantitatively accurate.
SUMMARY
The rise of antibiotic resistance threatens modern medicine; to combat it new diagnostic methods are required. Sequencing the whole genome of a pathogen offers the potential to accurately determine which antibiotics will be effective to treat a patient.
A key limitation of this approach is that it cannot classify rare or previously unseen mutations. Here we demonstrate that alchemical free energy methods, a well-established class of methods from computational chemistry, can successfully predict whether mutations in Staphylococcus aureus dihydrofolate reductase confer resistance to trimethoprim. We also show that the method is quantitatively accurate by calculating how much the most common resistance-conferring mutation, F99Y, reduces the binding free energy of trimethoprim and comparing predicted and experimentally measured minimum inhibitory concentrations for seven different mutations. Finally, by considering up to 32 free energy calculations for each mutation, we estimate its specificity and sensitivity.
INTRODUCTION
Resistance of bacteria to the antibiotics used to treat them is a substantial and growing global threat to human health (Davies, 2013; World Economic Forum, 2013) . Measures to counter the emergence of antibiotic resistance are restricted by the limitations of conventional diagnostic microbiology. This predominantly still relies on culture-based, phenotypic identification of bacteria, followed by growth in the presence of different antibiotic concentrations to detect resistance. The process is labor intensive, takes days or even weeks depending on the growth rate of the organism in question, is expensive, and open to subjective interpretation. Genetic approaches, particularly those based on sequencing the entire genome of a pathogen (Didelot et al., 2012; Kö ser et al., 2014) , have the potential to be faster and cheaper. Inferring the phenotype of an infecting pathogen from whole-genome sequence data by considering known resistance genes or mutations has already been shown to be reasonably accurate for a range of pathogens (Gordon et al., 2014; Walker et al., 2015; Pankhurst et al., 2016; Bradley et al., 2015) , and has recently been implemented in the UK for the routine diagnosis of Mycobacterium tuberculosis infections (Walker et al., 2017) . New mutations, however, continually arise, and a genetics-based clinical microbiology service therefore also needs to be able to predict the effect of novel mutations. In this paper we demonstrate that molecular-based computational chemistry methods can predict whether individual protein mutations confer resistance to an antibiotic.
As proof of principle we have investigated the effect of mutations to Staphylococcus aureus dihydrofolate reductase (DHFR) on the binding of the antibiotic trimethoprim (TMP) ( Figure 1A ). S. aureus is a clinically important Gram-positive pathogen and has been the focus of much research due to the development of methicillin-and vancomycin-resistant strains, known as MRSA and VRSA, respectively. TMP, usually administered as co-trimoxazole (trimethoprim-sulfamethoxazole), has a long history of treating S. aureus infections (Tong et al., 2015) , including common skin and soft tissue infections caused by MRSA strains (Nurjadi et al., 2014) . TMP competes with the natural substrate, dihydrofolic acid (DHA) ( Figure 1A) , for binding to DHFR, thereby preventing DHFR catalyzing the conversion of DHA to tetrahydrofolic acid. Since tetrahydrofolate is essential for the biosynthesis of thymidylate, purine nucleotides, and some amino acids, arresting the production of DHA inhibits bacterial growth. Resistance to TMP in S. aureus can either arise from mutations in the chromosomal gene dfrB, or from the introduction of other naturally resistant genes (dfrA, dfrG, and dfrK) via plasmids (Lowy, 2003; Nurjadi et al., 2014) . Here we focus on seven mutations in the dfrB chromosomal gene. We have chosen this gene for five reasons: (1) a series of resistanceconferring and no-effect mutations have been identified via whole-genome sequencing of isolates from patient infections (Gordon et al., 2014) , as well as by more traditional methods, (2) the most common resistance-conferring mutation is a very small chemical change (Phe / Tyr) and this is therefore a challenging test for any predictive approach, (3) DHFR is a small, soluble protein that has been well studied, (4) several experimental structures exist of S. aureus DHFR bound to TMP ( Figure 1B ) (Dale et al., 1997; Oefner et al., 2009; Heaslet et al., 2009) , and (5) there is published quantitative biophysical data on how the most common resistant-conferring mutation in S. aureus affects the binding of TMP to DHFR (Pires et al., 2015; Oefner et al., 2009; Dale et al., 1997; Frey et al., 2010 Frey et al., , 2012 . Since this is a classification problem we emphasize the importance of having negative controls (that is, mutations that are known to have no effect). This underscores the vital importance of clinical wholegenome sequencing studies as these naturally identify large numbers of such mutations.
Our hypothesis is that chromosomal mutations in an open reading frame will confer resistance if the mutation causes the antibiotic molecule to bind less well to the encoded protein, while, crucially, not significantly affecting how well the natural substrate binds. This is only one of several mechanisms by which bacteria can evolve resistance to antibiotics (Blair et al., 2014) . Other mechanisms include the introduction, by horizontal gene transfer, of genes encoding either proteins that degrade antibiotics, for example b-lactamases which are common in Gramnegative bacteria, or, as mentioned above, naturally resistant versions of chromosomal proteins. The overexpression of efflux pumps can reduce the concentration of the antibiotic within the bacterium to below effective levels or the cell well can simply be impenetrable to most antibiotics, the most notable example of this being M. tuberculosis.
The binding free energy (DG) is the thermodynamic quantity that captures how strongly a small molecule, like an antibiotic, is bound to a protein. Our hypothesis therefore distills down to calculating how a specific mutation affects the binding free energies, relative to the wild-type (wt), of both TMP and DHA
While it would be trivial for a mutation to disrupt the binding of the antibiotic (i.e., DG mutant TMP >DG wt TMP and so DDG TMP > 0), it is difficult for a mutation to simultaneously not disrupt the binding of the natural substrate (i.e., DG mutant DHA $ DG wt DHA leading to DDG DHA $ 0). For a mutation to give rise to a viable strain of S. aureus that is resistant to TMP, a first estimate of a binding free energy criterion is therefore DDG TMP > 0 and DDG DHA $0. By making some simple assumptions and applying kinetic theory, we will relate these changes in binding free energies to the minimum inhibitory concentrations (MICs) of the antibiotics. This is the quantity measured by clinical microbiology laboratories, and we are able, through MIC distributions published by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), to derive more sophisticated criteria based on clinical data.
To calculate how the binding free energy of either the antibiotic or the natural substrate changes upon introduction of the mutation we will apply Hamiltonian-exchange thermodynamic integration, an alchemical free energy method (Fowler et al., 2005 (Fowler et al., , 2007 Gilson and Zhou, 2007; Michel et al., 2010; Chodera et al., 2011; Gapsys et al., 2015a; Perez et al., 2016; Abel et al., 2017) . Alchemical free energy methods are derived from classical statistical mechanics, and calculate the cost of perturbing a chemical moiety, such as an amino acid side chain, into another using a series of classical molecular dynamics simulations; hence they are dubbed ''alchemical.'' There are no free parameters, and so in theory are exact, although in practice there are always likely to be errors due to imperfections in the parametrization of the molecules and the incomplete exploration of the dynamical phase space of the system during the simulations. We will not consider here other methods of calculating or estimating binding free energies, such as computational docking, ''endpoint'' methods, or protein design or stability algorithms, since they are unlikely, in our opinion, to capture the subtlety of the molecular perturbations. Since each free energy calculated by an alchemical free energy method requires a number of molecular dynamics simulations, this approach potentially requires large amounts of computational resource; however, given the continued increase in computing speeds this class of methods is coming of age and is beginning to find application (Wang et (Oefner et al., 2009 ). Three of the mutations, colored red (F99Y, F99Y/L21V, andL41F), were previously shown to confer resistance to TMP, while the remaining four, colored blue (F123L, A135T, V76A, and I83V), remained susceptible to the action of the antibiotic (Gordon et al., 2014) . This classification was confirmed by independent measurement of TMP MICs for each mutant (Tables S1-S3). These colors are used throughout.
Traditionally, a single calculation would be run for each perturbation (here a protein mutation) and the error in the free energy estimated by, e.g., dividing the simulation trajectories into ''independent'' sections by calculating a correlation time. Since this is a clinically important problem where the accuracy of the classification, and potentially also minimizing the time taken to return a prediction, are essential, we shall instead run a large ensemble of relatively short thermodynamic integration calculations for each mutation, simplifying the estimation of confidence intervals, as well as, subject to having sufficient computational resource, potentially reducing the time to solution. In the second half of the paper we will estimate the sensitivity and specificity of our method.
RESULTS
Clinically a mutation is described as resistant if the minimum concentration of an antibiotic that inhibits the growth of the bacteria is greater than a reference concentration. According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2016), S. aureus is defined as not susceptible to TMP (i.e., resistant) if its MIC is R 4 mg/L. Since TMP is a competitive inhibitor of DHFR and, assuming Michaelis-Menten enzyme kinetics (Price et al., 2009) , then as shown in the STAR Methods, if we assume that the mutation only affects the dissociation equilibrium constant of the antibiotic (K i ) we can derive a simple binding free energy-based resistance criterion, DDG TMP R0:8 kcal=mol:
This assumes that the enzyme rate constant and the concentrations of the enzyme and the substrate are all unaffected by the mutation. Alternatively, if we allow the protein mutation to affect the dissociation constants of both the inhibitor and the natural substrate, then we find a second resistance criterion, DDG TMP À DDG DHA R0:8 kcal=mol:
This is a more nuanced view of how resistance can arise: resistance is conferred if a mutation increases how well the natural substrate binds (DDG DHA <0), or if it decreases how well the antibiotic binds (DDG TMP >0). It is likely, however, that large changes in the magnitude of DDG DHA will affect the action and turnover rate of the enzyme and so, in practice, there will be a limit on how much a mutation can affect the binding of the natural substrate. Applying either of the above criteria generates a prediction of whether a mutation confers resistance or not and one of the aims of this paper is to assess if criterion R2 is more accurate and precise than R1. For either resistance criterion to classify a mutation as conferring resistance (or having no effect) the relevant free energy in R1 or R2 must lie demonstrably one side of the 0.8 kcal/mol threshold or the other; if the confidence limits bracket the threshold, then either criterion must return a classification of ''unknown.'' This is a small departure from most culture-based microbiology tests which simply return a binary ''resistant'' or ''susceptible'' classification.
We chose a series of mutations in the chromosomal gene dfrB identified by whole-genome sequencing of S. aureus clinical infections from two hospitals in the UK (Gordon et al., 2014) . As expected, by far the most common naturally occurring TMP resistance-conferring mutation in S. aureus DHFR was F99Y (Gordon et al., 2014; Dale et al., 1997) . Several studies have shown that this common mutation reduces the binding free energy of TMP to S. aureus DHFR by 2.0 ± 0.2 kcal/mol (Dale et al., 1997; Oefner et al., 2009; Frey et al., 2010 Frey et al., , 2012 Pires et al., 2015) , equivalent to a 24-fold increase in the dissociation constant, K i . This is a large effect given the mutation only replaces a hydrogen by a hydroxyl. Two further resistanceconferring mutations were chosen: L41F, which has also been observed previously (Vickers et al., 2009) , and the double mutation F99Y/L21V, which has not. The related triple mutation F99Y/L21V/N60I was, however, identified as resistant 20 years ago (Dale et al., 1997) . Mutating two residues simultaneously is likely to lead to convergence issues, and we therefore decomposed the double F99Y/L21V mutation into two separate mutations, F99Y and Y99L21V, summing the free energies to obtain the result for the double mutation (Klimovich et al., 2015) . Although it has not yet been observed in isolation, we also calculated the effect of the isolated L21V mutation, allowing us to test the additivity of these mutations. Both the L41F and F99Y/L21V mutations are rare, only being observed once each among nearly 1,000 UK clinical isolates (Gordon et al., 2014) . Any classification method must be able to distinguish true positives from true negatives, and therefore we also studied the effect of four mutations in S. aureus DHFR that were each detected multiple times in the isolate collection and had no effect on the action of TMP based on the results of conventional drug susceptibility testing. These were F123L, A135T, V76A, and I83V ( Figure 1B) , and are negative controls.
To confirm the phenotype of these seven mutations, and to provide a consistent quantitative dataset, a subset of the clinical isolates that were sequenced as part of the previous study (Gordon et al., 2014) were retrieved and re-tested as described in the STAR Methods. The TMP MICs were determined for each patient isolate (Tables S1 and S2); up to five independent measurements were obtained, depending on how many clinical isolates of that mutation existed. The values obtained agree well with both MIC values recorded by Public Health England during routine testing (Table S3 ) and those previously reported in the literature (Pires et al., 2015; Dale et al., 1997; Frey et al., 2010 Frey et al., , 2012 Vickers et al., 2009) .
Alchemical Free Energy Calculations Accurately Predict Which Mutations Confer Resistance
Using our chosen alchemical free method (see STAR Methods) we calculated how the free energy of binding of both TMP (DDG TMP ) and DHA (DDG DHA ) varies upon introducing each of the seven clinically observed mutations. Thirty-two values of DDG TMP and DDG DHA were calculated for each mutation, making 512 DDG values in total. Since each pair of (DDG TMP ,DDG DHA ) values necessitated the calculation of 13 different DG values ( Figure S5 ), which makes 3,328 separate free energies. Since they originate from separate sets of simulations, each DDG value is assumed to be independent, and therefore it is straightforward to examine how the values of DDG TMP and DDG DHA converge as the number of calculations, n, increases ( Figure 2 ). As expected, the uncertainty in the free energy is a maximum around n = 3 and then falls as the number of calculations is increased. The mutations with the largest confidence intervals are also those which perturb the largest number of atoms (F99Y/L21V, L41F, and F123L).
The above analysis assumes that each DDG calculation is itself converged; the standard way to test this would be to compare the forward and reverse cumulative averages of each DDG value (Yang et al., 2004; Klimovich et al., 2015) . This is not possible here due to the large numbers of DDG values; instead we demonstrate that increasing or decreasing the proportion of each simulation that is discarded does not significantly alter either the calculated numerical values, or the resulting classification (Figures S1 and S2).
While our predicted value of DDG TMP for the common F99Y mutation (1.5 ± 0.2 kcal/mol) ( Figure 3A ; Table S4 ) does not agree within error with the mean value (2.0 ± 0.2 kcal/mol) of several previously published isothermal titration calorimetry (ITC) measurements (Pires et al., 2015; Oefner et al., 2009; Dale et al., 1997; Frey et al., 2010 Frey et al., , 2012 , there is considerable overlap between the predicted and experimental values. Furthermore, all three known resistance-conferring mutations (F99Y, F99Y/L21V, and L41F) are predicted to reduce how well TMP binds to DHFR (DDG TMP > 0; Figure 3B ; Table S4 ). Since these mutations were predicted to, on average, increase DDG TMP by significantly more than 0.8 kcal/mol, they are classi-fied as conferring resistance to TMP by criterion R1. Of the four negative control mutations, three are predicted to have ''no effect'' on the action of TMP, although the 0.8 kcal/mol threshold is just outside the confidence limits for the F123L mutation. Since the 95% confidence limits for the remaining I83V mutation cross the threshold, this mutation is classified as having an ''unknown'' phenotype.
But how do the mutations affect the binding of the natural substrate, DHA? In contrast to the binding of TMP, all the mutations, with the exception of L41F and I83V, are predicted to either have no effect on the binding of DHA, or to increase how strongly DHA binds to DHFR ( Figure 3C ; Table S5 ). By considering the mean values for all four no-effect mutants, we find they are not predicted to change the magnitude of DDG DHA by more than 0.5 kcal/mol, in line with our expectation that DDG DHA $0.
Plotting the mean values of DDG DHA against DDG TMP (Figure 4 ) allows us to classify the seven mutations using the second resistance criterion (R2). This condition predicts that all three known resistance-conferring mutations confer resistance to TMP, while of the four negative controls, three (V76A, A135T, and I83V) are correctly predicted to have no effect on the action of TMP. Since the confidence limits of the remaining F123L mutation straddle the 0.8 kcal/mol threshold, it is predicted to have an ''unknown'' (Tables S4 and  S5 ). For each mutation, the variation in the mean DDG value and its 95% confidence limits (calculated using the appropriate t statistic) are shown as a function of the number of calculations, n. The inset graphs show how the confidence limits vary with n and all have the same scale. The initial 20% of each simulation has been discarded to avoid equilibration effects.
effect. If the natural substrate binds more strongly to the enzyme (DDG DHA < 0), one could hypothesize that this should improve the turnover rate, if binding is the rate-limiting step. We speculate that L41F and I83V (especially the former) induce a fitness cost, since they reduce how well DHA binds to DHFR, while V76A, F99Y, and particularly F99Y/L21V, bring a fitness benefit, with the others have no effect on the fitness of the enzyme. Since the free energies for the L21V and Y99L21V mutations (Tables S4 (B) Applying resistance criterion R1 correctly classifies the F99Y, F99Y/L21V, and L41F mutations as conferring resistance to TMP. The mutation L21V is also predicted to confer resistance. Of the four mutations known to have no effect on the action of TMP, F123L, A135T, and V76A are correctly classified as not conferring resistance and I83V is classified as having an unknown effect. The fold change in the dissociation equilibrium constant (K i ) is also shown. Each value of DDG is the mean of 32 independent calculations (Tables S4 and S5) , and the bars represent 95% confidence limits, using the appropriate t statistic. The initial 20% of each simulation has been discarded to avoid equilibration effects. Discarding 10% or 50% of the data does not alter these conclusions ( Figures S1  and S2 ).
(C) The same calculations were repeated, but with DHA bound. With the exception of L41F and I83V, no mutation decreases how well DHA binds to DHFR, to within error. and S5) are identical, to within error, we conclude that the effects of the F99Y and L21V mutations on the binding of TMP or DHA in the double F99Y/L21V mutant are additive.
Predicting MICs
A stronger test of our approach is to compare against quantitative, rather than qualitative, data for all the mutations tested, rather than just F99Y. In the absence of quantitative binding data for the other mutations (as measured by, e.g., ITC), we can instead predict the MIC for each mutation using Equation 2 and then compare it with the experimentally observed mean MICs (Tables S1 and S2). As described in the STAR Methods, the TMP MICs were measured by bioMé rieux E-test. These have a roughly doubling ladder of antibiotic concentrations going from 0.002 to 32 mg/L, a range of 16,000-fold. At first glance, there is a good correlation between the predicted and observed MICs ( Figure 5 ). This is, however, not a thorough test since (1) the experimental values have an upper limit of >32 mg/mL, and so we cannot distinguish between the different resistance-conferring mutations, and (2) there are no mutations that confer an intermediate level of resistance. Despite this, five of the seven predicted MICs can be said to be in ''essential agreement,'' since they are within a single doubling dilution (within the 23 lines) of the reference method value (ISO, 2007) and, overall, it is promising that it appears possible to predict MICs to within a factor of 2-4. We conclude that alchemical free energy methods are not only able to distinguish resistance-conferring mutations from suscep-A B Figure 4 . The R2 Resistance Criterion Correctly Predicts the Effect of Six of the Seven Mutations, with F123L Being Classified as Having an Unknown Effect (A) Plots of how each mutation is predicted to affect the binding of DHA against TMP (i.e., Figures 3B versus 3C) for each of the 32 independent pairs of calculations. The region defined by the R2 resistance criterion is shaded gray. (B) Plotting the mean values with 95% confidence intervals demonstrates that the R2 resistance criterion correctly classifies all bar the F123 mutation which is predicted to have an unknown effect. The variation with n is shown in Figure S3 . All mutations are colored according to the same scheme as Figure 1. tible mutations, but also, by comparing with ITC data and MIC data, can make quantitatively accurate predictions, although more work is required before it will be possible to confirm that one can formally relate DDG values to MICs. This proof of principle study also suggests that a good level of confidence in the phenotype of a mutation can be obtained by only predicting the effect on the binding of the antibiotic (i.e., criterion R1), in this case TMP.
Classifying Mutations Using an Alchemical Free Energy Method Is Sensitive and Specific Given predictions made by this type of approach could, one day, be used to drive clinical decision making, it is essential to establish the sensitivity and specificity of the method. First, let us assume that our sets of 32 pairs of DDG TMP and DDG DHA values per mutation are representative. The classification performance of the method can then be modeled by repeatedly drawing (with replacement) samples containing n values of DDG TMP and n values of DDG DHA , and applying either resistance criterion to produce a classification. We repeated this bootstrapping approach 10,000 times at each value of 2 % n % 32, and a summary of the results at five distinct values of n˛{3,5,10,16,32} is shown in Figure 6 (see also Figure S4 ). Interestingly, even at small values of n, the method is unlikely to return an incorrect categorical prediction; the highest false categorization rate occurs when applying the R1 resistance criterion to the I83V mutation at n = 3, and even then our analysis suggests the method would have incorrectly classified this mutation as conferring resistance only 2.5% of the time, with an ''unknown'' result being returned in 91% of cases. We conclude that the method is robust in the sense that once n is large enough for it to return a definite categorization it is highly likely to be correct.
The performance of a binary classification process is usually assessed by considering the true-positive and true-negative rates of detection, often referred to as the sensitivity and specificity, respectively. These are given in Table 1 . Since our approach gives a ternary classification (''unknown'' in addition to ''resistant,'' and ''susceptible''), there are two ways one can define the sensitivity and specificity. The difference rises from whether one includes the uncharacterized cases in the numbers of false positives and false negatives, or whether these cases can be excluded, since the method has (correctly) not attempted a definitive classification. If we first consider the former, more conservative definition, then the sensitivities/specificities are relatively low at small values of n and increase with n, achieving 99.7/61.3% for the R1 resistance criterion and 78.6/72.8% for the R2 criterion at n = 10 before reaching 100.0/77.9% and 84.0/91.0% at n = 32, respectively (Table 1) . However, the proportion of uncharacterized cases fall dramatically from 37% (55%) for the first (second) resistance criterion at n = 3, to 11% (13%) at n = 32. If all these cases are excluded then all the sensitivities and specificities are R98%, suggesting that (1) the increase in the conservative estimates of the sensitivities and specificities is entirely driven by the decrease in the proportion of uncharacterized cases, and that (2) our previous observation that the method rarely incorrectly classifies a mutation is correct. We conclude that the main effect of increasing the number of free energy calculations used in a prediction is increasing the likelihood that a definite classification will be made. We cannot, although, conclude which resistance criterion is ''better'' since both the R1 and R2 resistance criteria struggle to classify two mutations each (F123L and I83V and F123L and L41F, respectively), even at high values of n. Difficulties in classifying a mutation are due to a combination of where it happens to fall relative to the two free energy thresholds on the (DDG TMP ,DDG DHA ) plane ( Figures 4 and S3) , and the variability between individual free energy calculations, which is related to the magnitude of the perturbation. The performance of either criteria therefore critically depends on which mutations have been selected to make up a test-set and, since we have only studied seven mutations, we cannot yet conclude which is preferable. Allowing a mutation to affect the binding of the natural substrate as well as the antibiotic is more elegant and hence one would expect the R2 resistance criterion to be more accurate, but it also requires 13/83 the number of free energy calculations ( Figure S5) .
One final possibility is to use the classifications from both criteria to make an ensemble prediction. The cases where both resistance criteria agree are trivial; the key question is how to classify mixed classifications, e.g., RU. Here we assume that a definitive classification (''resistant'' or ''susceptible'') will overrule any ''unknown'' classification and ''resistant'' will overrule ''susceptible.'' Hence if the results of applying the R1 and R2 resistance criteria can be represented as two letters, we shall define our ensemble rules for predicting resistance, susceptibility or unknown phenotypes as [RR,RU,UR,RS,SR], [SS,SU,US], and [UU], respectively. This ensemble method improves the classification performance, as measured by sensitivities and specificities (Table 1) , for these seven mutations at least. It is, however, slightly unsatisfying since it weakens the link between the effect of the mutation on how well the antibiotic binds to the protein and the effectiveness of the drug.
DISCUSSION
We have shown that alchemical free energy methods can predict whether mutations in S. aureus DHFR confer resistance or not to the antibiotic TMP. This paves the way for the introduction of such structural-based predictive methods into a genetics-based clinical microbiology service (Didelot et al., 2012; Kö ser et al., 2014) , allowing novel or insufficiently characterized mutations to be assessed, thereby mitigating one of the key weaknesses of genetics-based clinical microbiology. The potential benefits of transitioning from laboratory-to genetics-based microbiology in the clinical setting are large: a reduction in the time for drug susceptibility testing (especially for slow-growing pathogens such as M. tuberculosis), automatic epidemiological monitoring of the dispersal of specific resistance mechanisms, and ever-decreasing cost. The switch to a genetics-based clinical microbiology will ultimately lead to increased precision in antibiotic prescribing and reduced selection for antibiotic resistance. The clinical transition has just begun: in early 2017 Public Health England adopted wholegenome sequencing for routine drug susceptibility testing for M. tuberculosis infections (Walker et al., 2017) and other countries look likely to follow suit.
Establishing the accuracy and reproducibility of any predictive method is essential, especially if it could ultimately drive decisions in a clinical setting. We emphasize the vital importance of (1) having negative controls, which here was enabled by a previous clinical whole-genome sequencing study (Gordon et al., 2014) , (2) running multiple repeats, which has the additional benefit of simplifying the estimation of errors (Coveney and Wan, 2016) , and (3) systematically assessing the sensitivity and specificity of any method. The predicted values are inferred from how the mutation alters the relative binding of TMP and DHA using Equation 2. Note that since the bioMé rieux E-test does not measure above 32 mg/L, we have likewise cut off our predicted values at >32 mg/L. The predicted mean MIC for the F99YL21V mutation is very large ($2,400 mg/L) and therefore cannot be plotted in this range. Clinically, an S. aureus DHFR mutation is classified as resistant if the TMP MIC R4 mg/L (EUCAST, 2016); this region is shaded light gray. To aid interpretation, lines corresponding to a perfect correlation, and within factors of 23 and 43 are drawn. Since our calculations only yield a fold increase in the MIC, all the predicted MIC values are assumed to be relative to a wild-type (geometric mean) MIC of 1.1 mg/L (EUCAST, 2016). The mutations are colored according to the same scheme as Figure 1 .
Ultimately, for predictions made by a computational method such as ours to form part of an antimicrobial diagnostic workflow, it must satisfy the same standards as any new lab-based diagnostic method (ISO, 2007; U.S. Department of Health and Human Services Food and Drug Administration, 2009 ). The key metrics used to assess a new method are the major discrepancy (MD) rate (the proportion of cases where the reference method predicts the infection is sensitive to an antibiotic but the new method predicts it is resistant) and the very major discrepancy (VMD) rate (which is the proportion of cases the reference method predicts the infection is resistant but the new method predicts it is sensitive). For a diagnostic test to be approved by the International Standards Organization, both the MD and VMD must be <3%. As noted earlier, our method very rarely produces an incorrect definitive classification, and hence if ''unknown'' results can be excluded, our method, based on the results in this paper, satisfies these criteria. For example, if we take a ''worst'' case and consider only n = 3, then the VMD and MD for the first resistance criterion are 0.0% and 1.6%, respectively, while for the second resistance criterion the VMD and MD are 0.4% and 0.8%. In making this comparison, we are not claiming that this method is sufficiently accurate for use in a clinical microbiology workflow for diagnosing antibiotic-resistant infections (clearly many more mutations and proteins need to be tested) but rather, in combination with the sensitivity and specificity analysis, it does show that this method has the potential to predict the effect of novel and rare mutations on the action of antibiotics.
That the VMD rate is generally low but the proportion of classifications that are returned with an ''unknown'' phenotype falls as n, the number of free energy calculations used to make a prediction, increases, suggests that a sensible way of applying this method would be to initially run a small number of free energy calculations (say n = 5) and try classifying the effect of the mutation. If a definitive result is returned, our analysis suggests that it is probably correct and will not be altered by adding more data. Alternatively, if the method cannot classify the effect of the mutation, then one can run additional free energy The data in this figure were calculated by sampling-with-replacement and classifying 10,000 sets of n values of DDG TMP and n values of DDG DHA for n˛{3,5,10,16,32} A classification is then made from each bootstrapped sample of free energies, and the results shown here as a function of n, the number of measurements in each sample, depending on whether the (A) first or (B) second resistance criterion was applied. (C) The results of applying both criteria and taking a consensus is also shown. See Figure S4 . How well the R1 and R2 criteria classify each mutation can be understood by considering the location and relative variations of each mutation on the DDG DHA versus DDG TMP plane. This is shown in Figure 4 for n = 32 and examples of how it varies with n are shown in Figure S3 . calculations until a definitive ''resistant'' or ''no effect'' classification can be made. In this way, some mutations would be classified very quickly, and others, such as F123L or L41F, would take longer, as one would expect given the larger number of atoms being perturbed by the protein mutation.
Our approach has several weaknesses. Firstly, it assumes we know, at a molecular level, how an antibiotic works, specifically that it is a competitive inhibitor of an essential gene, and it is mutations in that gene that we wish to examine; this is often, but not always, true. Secondly, it requires a high-resolution experimental structure of the relevant bacterial protein with the antibiotic bound. Although the structural coverage of many bacterial genomes has more than doubled in the last 10 years, with some species now having the structures of over half their proteins determined (Khafizov et al., 2014) , the structural coverage of many pathogenic species remains low. In common with all applications of classical molecular dynamics, we are making two further key assumptions: (1) that our description of the molecular interactions is sufficiently accurate and (2) that we have adequately sampled the phase space of the molecules. The first is mitigated somewhat since it is protein atoms that are perturbed in the alchemical free energy calculation, and the protein force field has been extensively optimized (unlike in drug discovery where the atoms of a ligand, which inevitably are less well described, are perturbed). The second is mitigated by repeating calculations and allowing neighboring simulations to exchange their Hamiltonians according to a Metropolis criterion. It is also difficult to calculate the relative free binding energy for some mutations using alchemical free energy methods; those perturbing large numbers of atoms are, as we have seen for, e.g., F123L, take longer to converge. Finally, unlike in drug discovery where binding free energies (or equivalently dissociation equilibrium constants) are reported and to which one can directly compare predicted values of DDG, there is a paucity of binding free energy measurements for antibiotics. Instead the discipline of clinical microbiology measures and reports MIC values. It is possible, as we have done here, to relate the MIC to how the binding free energy changes upon the introduction of the mutation, but this requires several assumptions and is necessarily less direct.
Throughout this study we have calculated each component free energy (Equation 1; Figure S7 ) using the same number of l simulations for the same duration, regardless of what type of free energy is being calculated and the size of the mutation being studied. This is almost certainly highly inefficient; in future work we will examine how to optimize our approach so that the minimum amount of computational resource is required to produce an accurate classification in the shortest time possible. This will include determining if a large number of relatively short simulations (as done here) is more accurate, at least when it comes to classifying, than a smaller number of longer simulations. Although some progress has been made in recent years examining this question in the context of endpoint free energy methods (Coveney and Wan, 2016) , it has not yet been addressed for alchemical free energy calculations in general. Finally, it is only through the successful application of our approach to other proteins in other clinically important pathogens where resistance is increasingly a problem, that it will be possible to determine if our method, or another one like it also based on the chemistry The resulting sensitivities and specificities also increase with n. Two sets are given; the latter excludes all classifications with an unknown phenotype. All sensitivities and specificities are estimated by creating 10,000 samples of n values of DDG TMP and n values of DDG DHA by drawing-with-replacement from the larger set of 32 calculations. Results are given for the R1 and R2 resistance criteria. Applying a consensus where any definitive resistance or susceptible classification overrules any unknown classification is optimal. and structure of proteins, could, one day, be integrated into a genetics-based clinical microbiology pipeline.
SIGNIFICANCE
The discovery of antibiotics was one of humanity's greatest achievements in the 20th century; however, the evolution of antibiotic resistance by pathogens now threatens many advances of modern medicine. There is an urgent need for improved diagnostic tools so that resistant infections can be identified and treated appropriately. Analysis of wholegenome sequence data generated on affordable highthroughput platforms has the potential to allow resistant infections to be more rapidly and cheaply diagnosed in the clinic than conventional culture-based approaches. A key limitation of this approach is that it cannot identify whether rare or previously unseen mutations will be associated with drug susceptibility or resistance. Since many antibiotics are competitive inhibitors, we hypothesize that mutations that confer resistance reduce how well the drug binds the target protein, while not significantly altering the binding free energy of the natural substrate. In this case, predicting whether a mutation confers resistance is equivalent to calculating the effect of the mutation on the binding free energies of both the antibiotic and the natural substrate. By relating these quantities to the standard clinical microbiology metric, the minimum inhibitory concentration (MIC), we are able to derive two different clinically based criteria for classifying the effect of mutations and show that alchemical free energy methods, a well-established class of methods from computational chemistry, can not only predict which mutations confer resistance to trimethoprim, but are also quantitatively accurate.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
STAR+METHODS KEY RESOURCES TABLE

CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by the Lead Contact, Philip Fowler (Email: philip. fowler@ndm.ox.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The clinical isolates tested in this study were collected and sequenced as part of a larger study of clinical S. aureus isolates (Gordon et al., 2014) . Specifically, isolates containing one of the mutations studied here in the dfrB, but not containing any dfrA, dfrG and dfrK plasmid-encoded genes were identified by examining the genetic data -this can be found in the European Nucleotide Archive under study accession number ERP004655. All isolates containing the relevant dhfrB mutations, up to a maximum of five, were retrieved. Only single isolates containing F99Y/L21V and L41F dfrB were found. F123L and V76A were present in 3 and 4 isolates, respectively. For all others, five isolates were randomly chosen.
System Building and Equilibration
An experimental structure of S. aureus DHFR with trimethoprim (TMP) and NADPH bound (PDB:3FRE) was used to setup all simulations (Oefner et al., 2009) . Apo structures were created by removing TMP. The generalized AMBER forcefield in conjunction with AMBER ff99SB-ILDN (Lindorff-Larsen et al., 2010) was used throughout and all simulations were carried out using GROMACS 5.0.x (Abraham et al., 2015) . The mutations in the protein were represented using a dual topology and all GROMACS free energy topology files were prepared using pmx (Gapsys et al., 2015b) . Each protein was solvated by adding waters and ions resulting in a simulation unit cell of dimensions 7.1 3 6.4 3 6.0 nm containing 27,077-27,120 atoms. For each mutant, separate apo, TMP-and DHA-bound short equilibration simulations were run. First the energy of each system was minimised using the steepest descent algorithm for 1000 steps, then the dynamics of the system evolved for 2.5 ns with an integration timestep of 1 fs. Electrostatic forces were calculated using the particle mesh Ewald method with a real space cutoff of 1.2 nm. Van der Waals interactions were cutoff at 1.2 nm, with a switching function applied from 0.9 nm. A Langevin thermostat with a time constant of 2 ps was applied to keep the temperature at 310 K. The pressure was maintained at 1 atm by an isotropic Parinello-Rahman barostat with a time constant of 1 ps and a compressibility of 4.46310 À5 bar À1 . The lengths of all bonds involving a hydrogen were constrained using the LINCS algorithm. Since all the above simulations were run with l = 0 (i.e. wildtype sidechain), we then ran a short simulation to 'phase-in' the mutant sidechain using the Alchembed procedure (Jefferys et al., 2015) . This was repeated for different snapshots taken during the 2.5 ns equilibration trajectory and ensured that we had a range of starting conformations suitable for all the different alchemical and end-point simulations.
Alchemical Simulations and Calculations
A thermodynamic cycle was constructed ( Figure S7) and changes in the free energy of binding upon introduction of the mutation, DDG, was defined by a series of alchemical transformation free energies. We followed best practice and, when changing one sidechain into another, calculated three separate free energies (Klimovich et al., 2015) . This was repeated first for the apo protein (DG 1 ) and then the complex (DG 6 ). First the electrical charges on the perturbing atoms are removed (DG 11 & DG 61 ), before the van der Waals terms on the disappearing and appearing atoms are decoupled and coupled to the system, respectively (DG 12 & DG 62 ), using a softcore potential (Beutler et al., 1994; Zacharias et al., 1994) . Finally the electrical charges on the new atoms are switched on (DG 13 & DG 63 ). To keep the ligand within the active site, the distance between the protein and ligand centres of mass were restrained using a harmonic potential with a spring constant of 2000 kJ nm À1 mol À2 . The reference distances for TMP and DHA were 0.644 nm and 0.794 nm, respectively. The free energies of removing both restraints were calculated (DG 5 & DG 7 ). The final free energy is given by DDG = DG 5 + ðDG 61 + DG 62 + DG 63 Þ À ðDG 11 + DG 12 + DG 13 Þ À DG 7 :
(Equation 1)
We note that calculating a single value of DDG for trimethoprim requires eight independent free energy calculations, however, calculating a single value of DDG for the natural substrate, DHA, only requires an additional five free energy calculations since the free energies for introducing the mutation into the apo protein (DG 11 ,DG 12 ,DG 13 ) can be re-used. The computational cost of testing the second criterion (R2) is therefore 1.6253 that of testing the first criterion, assuming all free energies require the same amount of computational resource.
Each free energy was calculated by running either 8, 11 or 16 simulations at equally-spaced values of the progress parameter, l, between 0 and 1. To accelerate convergence, each set of 8, 11 or 16 simulations were coupled and attempted to exchange Hamiltonians every 1,000 steps (Sugita et al., 2000; Woods et al., 2003) . Each set was run for 0.25 ns, meaning each free energy calculation required between 26 and 52 ns of molecular dynamics simulation. Thirty two pairs of (DDG TMP ,DDG DHA ) were calculated for each mutation (Tables S4 and S5 ; Figure S5 ), 5 with 113l values, 5 with 163l values and 22 with 83l values. No correlation between the number of l values and the magnitude of the resulting value of DDG was detected. Calculating 32 pairs of DDG values for a single mutation therefore required 1.0 ms of molecular dynamics simulation. Eight mutations were calculated in total (since the F99YL21V mutation was decomposed into two separate mutations), making a total of 8.1 ms of molecular dynamics simulation. More daunting is that this is composed of 32,344 separate molecular dynamics simulations. These were stored and discovered using datreant, a flexible python module for handling heterogeneous file-based data (Dotson et al., 2016) .
The first derivative of the internal energy at the specified value of l, as well as the internal energy evaluated at all other values of l were written to disc every 0.1 ps. This permitted the free energy (DG) to be calculated using either the multi-state Bennett acceptance ratio estimator (MBAR) (Shirts and Chodera, 2008) by the alchemical-analysis python module (Klimovich et al., 2015) , or simple thermodynamic integration. Since no significant differences in DDG values were observed, with the mean unsigned error in a value of DDG being between 0.1-0.3 kcal/mol, depending on the number of atoms being perturbed, the latter was used for simplicity. A subset of the GROMACS input files is available for download allowing a single pair of DDG values to be calculated for each mutant from https://github.com/philipwfowler/amr-free-energy-dhfr-examples.
The simulation parameters are the same as for the equilibration simulations above, except the tolerance factor for the Ewald sum is decreased to 10 À6 to increase the accuracy of calculating electrostatic forces, as is standard in these types of calculations. To remove transient effects, the first 20% of each simulation was discarded. Discarding more (50%) or less (10%) of the data did not materially affect the results ( Figure S2 ). which implies that for a mutation to be classified as resistant, DDG TMP À DDG DHA R0:8 kcal=mol (R2)
Resistance criteria 1 and 2 provide two different approaches for operationally testing to see if a DHFR mutation confers resistance to TMP. These are labelled R1 and R2, respectively, in all figures and in the main body of the paper.
QUANTIFICATION AND STATISTICAL ANALYSIS
Throughout, standard errors were calculated at a confidence level of 95%, taking into account the appropriate t-statistic for the sample size. This assumes each calculated value of DG is independent, which is reasonable since they are started from different initial structures taken from the equilibration simulations and run using different random seeds.
